RxDoctor Payments Data

Robert Conciatori, MD

Psychiatry · Staten Island, NYNPI 1144345539

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 75 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$906
  • AbbVie$356
  • Takeda Pharmaceuticals U.S.A., Inc.$79
  • Lundbeck LLC$42
  • Otsuka America Pharmaceutical, Inc.$17
  • Bausch Health US, LLC$13

What the payments were for

  • Food & beverage$1,39799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,412 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$177,823
Medicare patients
291
Services billed
1,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$14,576
Alprazolam553$7,558
AzstarysSerdexmethylphen/Dexmethylphen12$4,749
Quetiapine Fumarate136$4,079
Lurasidone Hcl20$2,428
Aripiprazole57$1,980
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine72$1,924
Clonazepam194$1,671
Duloxetine Hcl95$1,604
Venlafaxine Hcl ErVenlafaxine Hcl53$1,003
Bupropion XlBupropion Hcl71$993
Zolpidem Tartrate179$871
Diazepam77$790
Sertraline Hcl104$786
Oxcarbazepine15$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$356$14,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →